171 related articles for article (PubMed ID: 28589772)
1. Report from European Association for the Study of the Liver: HCC Summit, Geneva, Switzerland, 2-5 February 2017.
Sacco R; Mirabile A; Giacomelli L; Bresci G; Attardo S; Cabibbo G
Future Oncol; 2017 Jun; 13(15):1297-1300. PubMed ID: 28589772
[TBL] [Abstract][Full Text] [Related]
2. EASL HCC summit: liver cancer management.
Sacco R; Gadaleta-Caldarola G; Galati G; Lombardi G; Mazza G; Cabibbo G
Future Oncol; 2014 May; 10(7):1129-32. PubMed ID: 24947253
[TBL] [Abstract][Full Text] [Related]
3. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
[TBL] [Abstract][Full Text] [Related]
4. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.
Poon D; Anderson BO; Chen LT; Tanaka K; Lau WY; Van Cutsem E; Singh H; Chow WC; Ooi LL; Chow P; Khin MW; Koo WH;
Lancet Oncol; 2009 Nov; 10(11):1111-8. PubMed ID: 19880065
[TBL] [Abstract][Full Text] [Related]
5. Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma.
Tholey DM; Ahn J
Gastroenterol Clin North Am; 2015 Dec; 44(4):761-73. PubMed ID: 26600218
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
Meringer H; Shibolet O; Deutsch L
World J Gastroenterol; 2019 Aug; 25(29):3929-3940. PubMed ID: 31413528
[TBL] [Abstract][Full Text] [Related]
7. Role of antiviral therapy in the management of hepatocellular carcinoma.
Guan YS; He Q
Anticancer Drugs; 2013 Apr; 24(4):337-43. PubMed ID: 23388161
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and management of hepatocellular carcinoma.
Kulik LM; Chokechanachaisakul A
Clin Liver Dis; 2015 Feb; 19(1):23-43. PubMed ID: 25454295
[TBL] [Abstract][Full Text] [Related]
9. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.
Ikeda K; Kawamura Y; Kobayashi M; Kominami Y; Fujiyama S; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Dig Dis Sci; 2017 Oct; 62(10):2932-2942. PubMed ID: 28884320
[TBL] [Abstract][Full Text] [Related]
10. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective.
Colombo M; Raoul JL; Lencioni R; Galle PR; Zucman-Rossi J; Bañares R; Seehofer D; Neuhaus P; Johnson P
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):639-51. PubMed ID: 23628963
[TBL] [Abstract][Full Text] [Related]
11. Inherited hepatocellular carcinoma.
Villanueva A; Newell P; Hoshida Y
Best Pract Res Clin Gastroenterol; 2010 Oct; 24(5):725-34. PubMed ID: 20955973
[TBL] [Abstract][Full Text] [Related]
12. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Kawaoka T; Aikata H; Teraoka Y; Inagaki Y; Honda F; Hatooka M; Morio K; Morio R; Kobayashi T; Nagaoki Y; Nakahara T; Hiramatsu A; Tsuge M; Imamura M; Kawakami Y; Chayama K
Oncology; 2017; 92(6):335-346. PubMed ID: 28245484
[TBL] [Abstract][Full Text] [Related]
13. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Cordie AA; Hassan EM; Omran DA; Leithy R; Elbaz TM
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):39-43. PubMed ID: 29064851
[TBL] [Abstract][Full Text] [Related]
14. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus.
Hung CH; Lee CM; Wang JH; Tung HD; Chen CH; Lu SN
J Gastroenterol Hepatol; 2005 Oct; 20(10):1553-9. PubMed ID: 16174073
[TBL] [Abstract][Full Text] [Related]
15. [Hepatocellular carcinoma].
Semela D; Heim M
Ther Umsch; 2011 Apr; 68(4):213-7. PubMed ID: 21452143
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus.
Tamori A; Nishiguchi S; Shiomi S; Hayashi T; Kobayashi S; Habu D; Takeda T; Seki S; Hirohashi K; Tanaka H; Kubo S
Am J Gastroenterol; 2005 Aug; 100(8):1748-53. PubMed ID: 16086711
[TBL] [Abstract][Full Text] [Related]
17. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis.
Masuzaki R; Yoshida H; Omata M
Oncology; 2010 Jul; 78 Suppl 1():17-23. PubMed ID: 20616579
[TBL] [Abstract][Full Text] [Related]
18. Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?
Cabibbo G; Celsa C; Cammà C; Craxì A
Liver Int; 2018 Dec; 38(12):2108-2116. PubMed ID: 29935096
[TBL] [Abstract][Full Text] [Related]
19. Interventional oncology for hepatocellular carcinoma.
Delicque J; Boulin M; Guiu B; Pelage JP; Escal L; Schembri V; Assenat E; Fohlen A
Clin Res Hepatol Gastroenterol; 2016 Nov; 40(5):530-537. PubMed ID: 27055387
[TBL] [Abstract][Full Text] [Related]
20. High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.
Chen TM; Lin CC; Huang PT; Wen CF
Tumour Biol; 2016 Jun; 37(6):7129-37. PubMed ID: 26662957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
